We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
34. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
35. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
36. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
37. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
38. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
39. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
40. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
41. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
42. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
43. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
45. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
46. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
47. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
48. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
49. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
50. Cow’s milk allergy: the future
- Dr. Carina Venter
-
51. Cow's milk allergy: management
- Dr. Carina Venter
-
52. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
53. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
54. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
55. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
56. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
57. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
58. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
59. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
60. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
61. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
63. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
64. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
65. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
66. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
67. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
68. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
69. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
70. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
71. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
72. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
73. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
74. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
75. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
76. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
77. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
78. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
79. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
80. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
81. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
82. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
83. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
84. AI and big data in drug discovery
- Mr. Ed Addison
-
85. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
86. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
87. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
88. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
89. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
90. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
91. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
92. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
93. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
94. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
95. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
96. New drugs for asthma
- Prof. Peter Barnes
-
97. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
98. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Factors that modulates inflammatory response
- Knockdown of the α7nAChR
- Expression of a7nAChR by primary RA FLS
- Expression of a7nAChR in several cell types
- VNS attenuates acute inflammation
- Cholinergic anti-inflammatory pathway
- Aggravation of collagen-induced arthritis
- Anti-collagen II antibodies in plasma
- Antigen-specific stimulation of splenocytes
- Reduced arthritis after oral nicotine treatment
- Treatments with a7nAChR activator or agonist (1)
- Treatments with a7nAChR activator or agonist (2)
- TNF level after treatment with a7nAChR regulators
- The cholinergic anti-inflammatory pathway and CIA
- Cholinergic pathway and chronic inflammation
- Heart rate variability
- Autonomic balance in individuals at risk of RA
- RHR ≥ 70 bpm in those at risk of developing RA
- RHR is higher in individuals at risk of RA
- Proposed novel strategy for RA treatment
- VNS reduces signs and symptoms of CIA
- Inflammatory reflex activation and cytokine
- The effects of VNS on cytokine production
- Inflammatory reflex activation reduces TNF level
- Inflammatory reflex activation and IL-6 & IL-1β
- Open label trial in RA with withdrawal period
- Mean change in DAS28-CRP through day 84
- Chronic VNS reduces LPS-induced TNF release
- Endurance of the therapeutic effect of VNS
- Sustained decrease in HAQ-DI
- Independent confirmation of our results in RA&CD
- Conclusions
- Acknowledgements
Topics Covered
- Role of the cholinergic anti-inflammatory pathway or inflammatory reflex in chronic inflammation
- How its role was discovered in a prototypic immune-mediated inflammatory disease (rheumatoid arthritis)
- Bioelectronic vagus nerve stimulation effect on cytokine production and reduction of disease activity in chronic inflammatory disease
- Opportunity to treat a wide variety of conditions using bioelectronics
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Tak, P.P. (2019, September 26). Bioelectronic medicine: immunomodulation by vagus nerve stimulation [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/GYZM8921.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Tak has previously been a consultant to SetPoint Medical and a Member of the Board of Directors of Galvani Bioelectronics.
Bioelectronic medicine: immunomodulation by vagus nerve stimulation
Published on September 26, 2019
27 min
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
I'm Paul Peter Tak,
I'm a Professor of Medicine at the Amsterdam University Medical Center.
What if I told you that you can treat chronic immune mediated
inflammatory disease by electrons rather than by small molecules?
In other words, what if I told you that we can treat patients with
bio-electronic medicine rather than with tablets or injections?
Well, we can, and that's what I'm going to show you,
and I will show you how we got to this discovery in chronic autoimmune disease.
0:36
It starts with the identification of factors that are involved in
the modulation of the response in rheumatoid arthritis in
the key effective cell called the fibroblast-like synoviocytes
and we obtained synovial tissue samples from patients with active rheumatoid arthritis,
so they have an actively inflamed joint with pain and swelling,
and we obtained these samples using arthroscopy.
Then in the lab,
we cultured these fibroblast-like synoviocytes,
we seeded them using a library of more than 2,000
adenoviral shRNAs against 807 transcripts.
Then five days after transduction,
we added TNF to the medium and read out the production of key
cytokines/chemokine involved in the pathogenesis
of rheumatoid arthritis namely Interleukin 8,
and we also looked at the production of degrading enzymes,
matrix metalloproteinases because these are involved in
the destruction of the bone and cartilage in rheumatoid arthritis,
which is a chronic inflammatory disease of the joints.